Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 16/20 | 0.55 |
| ▸ | FPR1 | P21462 | 5/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487001 | 0.90 | FPR2 (0.53) | FPR2FPR1CASP3 | |
| SCHEMBL13887434 | 0.85 | CASP3 (0.45) | FPR2FPR1CASP3 | |
| SCHEMBL4480037 | 0.85 | CASP3 (0.45) | FPR2FPR1CASP3 | |
| SCHEMBL8327055 | 0.82 | CASP3 (0.49) | FPR2FPR1CASP3 | |
| SCHEMBL8326106 | 0.79 | CASP3 (0.47) | FPR2FPR1CASP3 | |
| SCHEMBL20582050 | 0.77 | FPR2 (0.66) | FPR2FPR1 | |
| SCHEMBL4338889 | 0.76 | CCR1 (0.48) | FPR2FPR1CASP3 | |
| SCHEMBL28391420 | 0.76 | FPR2 (0.62) | FPR2FPR1 | |
| SCHEMBL4472817 | 0.75 | F10 (0.43) | FPR2FPR1CASP3 | |
| SCHEMBL14601912 | 0.75 | F10 (0.43) | FPR2FPR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | SMALLHEER JOANNE M | 2006-11-02 | — | — | US | disclosed |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247243-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, F5 | FPR2 3867/4885FPR1 2550/4885CASP3 1131/4885 |
| US-20040006062-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, SPINT2, PRSS1 | FPR2 3872/4885FPR1 1791/4885CASP3 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.